BI 685509 Dose finding PoCC in DKD
Research payments
$2,020,603
Through program year 2023, $2,020,603 in research payments was reported against BI 685509 Dose finding PoCC in DKD, across 95 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $233,573 | 22 |
| 2022 | Research | $1,093,968 | 47 |
| 2021 | Research | $693,062 | 26 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Adam Frome Shenandoah, TX Named on 8 payments
- Sayed Tabatabai San Antonio, TX Named on 7 payments
- Kiranjit Dhillon Norfolk, VA Named on 5 payments
- Juan Olivero Houston, TX Named on 5 payments
- Mark Vishnepolsky Las Vegas, NV Named on 4 payments
- Pablo Pergola San Antonio, TX Named on 4 payments
- Charles Harper Norfolk, NE Named on 4 payments
- Gregory Greenwood Winston Salem, NC Named on 4 payments
- Jose Cardona Hialeah, FL Named on 4 payments
- Lenita Hanson Port Charlotte, FL Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.